A recent prediction from industry analysts shows the Atopic Dermatitis space might see some new life in the months ahead. With multiple promising treatments either soon to be submitted for or pending final regulatory approval, the current top treatment Dupixent by Regeneron and Sanofi looks to finally face some competition. With over 200 million adults suffering from Atopic Dermatitis, the most common dermatological disease, the potential of these treatments offering relief is welcome news. Read more about this prediction and the companies involved in the article linked below.